METTL3/YTHDF2 M6A Axis Promotes the Malignant Progression of Bladder Cancer by Epigenetically Suppressing RRAS

Overview

Journal Oncol Rep

Specialty Oncology

Date 2023 Mar 24

PMID 36960869

Authors

Jie-Xun Chen

Dong-Ming Chen

Dong Wang

Yi Xiao

Shuai Zhu

Xian-Lin Xu

Affiliations

Soon will be listed here.

Abstract

The present study aimed to explore the potential roles of the methyltransferase‑like 3 (METTL3)‑mediated methylation of RAS related (RRAS) mRNA in the tumorigenesis and development of bladder cancer (BCa). For this purpose, the relative expression levels of METTL3 in BCa specimens and cell lines were measured using reverse transcription‑quantitative PCR (RT‑qPCR) and western blot analysis. The association between the METTL3 expression level and the clinical characteristics of patients with BCa was analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis databases. Cellular experiments were performed to confirm the effects of METTL3 on the proliferative, migratory and invasive capacities of BCa cells. RT‑qPCR, western blot analysis, methylated RNA immunoprecipitation (MeRIP)‑qPCR and dual‑luciferase report assays were utilized to verify the METTL3/RRAS/YTH N‑methyladenosine (m6A) RNA binding protein 2 (YTHDF2) regulatory axis in BCa. The results revealed that METTL3 expression was markedly increased in BCa specimens and cell lines, and was associated with poor clinical characteristics of patients with BCa. and assays demonstrated that the silencing of METTL3 markedly suppressed the proliferative, migratory and invasive capacities of BCa cells. MeRIP‑PCR and dual‑luciferase report assays indicated that METTL3 could bind to the m6A sites of RRAS mRNA and suppress the transcriptional activity of RRAS. YTHDF2 could recognize the m6A sites of RRAS and mediate RRAS degradation. On the whole, the findings of the present study reveal the pivotal role of METTL3‑catalyzed m6A modification in BCa tumorigenesis and development. The change could facilitate BCa tumor growth and metastasis by suppressing RRAS expression in an m6A YTHDF2‑dependent manner. Targeting the METTL3/RRAS/YTHDF2 regulatory axis may thus prove to be a promising strategy for the diagnosis and therapy of BCa.

Citing Articles

Loss of YTHDC1 mA reading function promotes invasiveness in urothelial carcinoma of the bladder.

Xu J, Koch J, Schmidt C, Nientiedt M, Neuberger M, Erben P Exp Mol Med. 2024; 57(1):118-130.

PMID: 39741187 PMC: 11799412. DOI: 10.1038/s12276-024-01377-x.

METTL3 promotes osteoblast ribosome biogenesis and alleviates periodontitis.

Zhang Y, Kong Y, Zhang W, He J, Zhang Z, Cai Y Clin Epigenetics. 2024; 16(1):18.

PMID: 38267969 PMC: 10809637. DOI: 10.1186/s13148-024-01628-8.

Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs.

Sakai N, Kamimura K, Terai S Pharmaceutics. 2023; 15(9).

PMID: 37765160 PMC: 10536625. DOI: 10.3390/pharmaceutics15092190.

Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics.

Janin M, Davalos V, Esteller M Cancer Metastasis Rev. 2023; 42(4):1071-1112.

PMID: 37369946 PMC: 10713773. DOI: 10.1007/s10555-023-10120-3.

References

Hu L, Yu Y, Shen Y, Huang H, Lin D, Wang K . Ythdf2 promotes pulmonary hypertension by suppressing Hmox1-dependent anti-inflammatory and antioxidant function in alveolar macrophages. Redox Biol. 2023; 61:102638. PMC: 9975317. DOI: 10.1016/j.redox.2023.102638. View

Raza A, Pandey M, Jin Q, Mulder K . km23-1/DYNLRB1 regulation of MEK/ERK signaling and R-Ras in invasive human colorectal cancer cells. Cell Biol Int. 2019; 44(1):155-165. PMC: 7007335. DOI: 10.1002/cbin.11215. View

Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M . The mA methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene. 2019; 38(19):3667-3680. DOI: 10.1038/s41388-019-0683-z. View

Joensen U, Maibom S, Poulsen A . Surgical Management of Muscle Invasive Bladder Cancer: A Review of Current Recommendations. Semin Oncol Nurs. 2021; 37(1):151104. DOI: 10.1016/j.soncn.2020.151104. View

Shen D, Wang B, Gao Y, Zhao L, Bi Y, Zhang J . Detailed resume of RNA mA demethylases. Acta Pharm Sin B. 2022; 12(5):2193-2205. PMC: 9136571. DOI: 10.1016/j.apsb.2022.01.003. View

Li X, Ma S, Deng Y, Yi P, Yu J . Targeting the RNA mA modification for cancer immunotherapy. Mol Cancer. 2022; 21(1):76. PMC: 8924732. DOI: 10.1186/s12943-022-01558-0. View

Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W . METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 2022; 21(1):60. PMC: 8864846. DOI: 10.1186/s12943-021-01447-y. View

Chen J, Fang Y, Xu Y, Sun H . Role of m6A modification in female infertility and reproductive system diseases. Int J Biol Sci. 2022; 18(9):3592-3604. PMC: 9254474. DOI: 10.7150/ijbs.69771. View

Lee Y, Choe J, Park O, Kim Y . Molecular Mechanisms Driving mRNA Degradation by mA Modification. Trends Genet. 2020; 36(3):177-188. DOI: 10.1016/j.tig.2019.12.007. View

10.

Nason G, Ajib K, Tan G, Kulkarni G . Bladder-sparing treatment options in localized muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2020; 20(3):179-188. DOI: 10.1080/14737140.2020.1736565. View

11.

Li H, Prever L, Hsu M, Lo W, Margaria J, De Santis M . Phosphoinositide Conversion Inactivates R-RAS and Drives Metastases in Breast Cancer. Adv Sci (Weinh). 2022; 9(9):e2103249. PMC: 8948670. DOI: 10.1002/advs.202103249. View

12.

Qu X, Zhang Y, Sang X, Ren D, Zhao H, Wong S . Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer. Cancers (Basel). 2022; 14(13). PMC: 9264946. DOI: 10.3390/cancers14133195. View

13.

Liu S, Chen X, Lin T . Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives. J Adv Res. 2022; 39:187-202. PMC: 9263750. DOI: 10.1016/j.jare.2021.11.010. View

14.

Zhang F, Liu H, Duan M, Wang G, Zhang Z, Wang Y . Crosstalk among mA RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application. J Hematol Oncol. 2022; 15(1):84. PMC: 9258089. DOI: 10.1186/s13045-022-01304-5. View

15.

Wei Y, Zhang F, Zhang T, Zhang Y, Chen H, Wang F . LDLRAD2 overexpression predicts poor prognosis and promotes metastasis by activating Wnt/β-catenin/EMT signaling cascade in gastric cancer. Aging (Albany NY). 2019; 11(20):8951-8968. PMC: 6834412. DOI: 10.18632/aging.102359. View

16.

Chen X, Zhou X, Wang X . mA binding protein YTHDF2 in cancer. Exp Hematol Oncol. 2022; 11(1):21. PMC: 8981655. DOI: 10.1186/s40164-022-00269-y. View

17.

Yu H, Yang X, Tang J, Si S, Zhou Z, Lu J . ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis. Mol Ther Nucleic Acids. 2020; 23:27-41. PMC: 7744648. DOI: 10.1016/j.omtn.2020.10.031. View

18.

Zhu Y, Peng X, Zhou Q, Tan L, Zhang C, Lin S . METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death Dis. 2022; 13(4):358. PMC: 9016063. DOI: 10.1038/s41419-022-04817-6. View

19.

Zhou H, Mao L, Xu H, Wang S, Tian J . The functional roles of mA modification in T lymphocyte responses and autoimmune diseases. Cytokine Growth Factor Rev. 2022; 65:51-60. DOI: 10.1016/j.cytogfr.2022.04.004. View

20.

Jordan B, Meeks J . T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2018; 16(1):23-34. DOI: 10.1038/s41585-018-0105-y. View